ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 786

Smoking As a Risk Factor for Giant Cell Arteritis: A Systematic Review and Meta-Analysis

David Brennan1, Patompong Ungprasert2, Kenneth J. Warrington2 and Matthew J. Koster2, 1Internal Medicine, Mayo Clinic, Rochester, MN, 2Rheumatology, Mayo Clinic, Rochester, MN

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: giant cell arteritis, meta-analysis, temporal arteritis and tobacco use

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 5, 2017

Title: Vasculitis Poster I: Large Vessel Vasculitis

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Tobacco smoking is a well-established risk factor for the development of several autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus.  A similar association between smoking and giant cell arteritis (GCA) has been suspected but remains unclear due to limited study size and conflicting epidemiologic data. In order to further investigate the association between smoking and the development of GCA we conducted a systematic review and meta-analysis.

Methods: Two investigators (D.B. and M.K.) independently searched published studies indexed in MEDLINE and EMBASE from inception to February 2017 using the terms “giant cell arteritis,” “temporal arteritis,” “cranial arteritis,” and “Horton disease.” Recent conference abstracts available online were also reviewed.   The following inclusion criteria were used: 1) original observational study comparing patients with GCA to healthy controls; 2) inclusion of smoking history; 3) provision of absolute numbers and/or statistical comparisons with 95% confidence intervals.  Study eligibility was independently determined by the two investigators, with disagreements reviewed by a third investigator (P.U.) and resolved by consensus.  RevMan 5.3 software was used for the data analysis.  Point estimates and standard errors were extracted from individual studies and were combined by the generic inverse variance method of DerSimonian and Laird.  Given the high likelihood of between-study variance, we used a random-effect model rather than a fixed-effect model.  Statistical heterogeneity was assessed using the Cochran’s Q test.  

Results: The initial search yielded 3312 articles.  Of these, thirteen studies (8 prospective and, 5 retrospective case-control studies) with unique cohorts were identified and included in the primary analysis (ever vs. never smoking history).  Patients in the GCA cohort were more likely to have a history of smoking with an odds ratio of 1.19 (95% CI, 1.01 – 1.39) [Figure 1A].  Considerable heterogeneity was present (I2 = 85%).  Five of these studies included information on current smoking status. One additional study, which only reported current smoking status, was also included.  The GCA cohort showed an association with current tobacco use with an odds ratio of 1.18 (95% CI, 1.01 – 1.38) [Figure 1B].

Conclusion: Our study demonstrated a statistically significant increased risk of GCA among smokers compared to non-smokers.


Disclosure: D. Brennan, None; P. Ungprasert, None; K. J. Warrington, None; M. J. Koster, None.

To cite this abstract in AMA style:

Brennan D, Ungprasert P, Warrington KJ, Koster MJ. Smoking As a Risk Factor for Giant Cell Arteritis: A Systematic Review and Meta-Analysis [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/smoking-as-a-risk-factor-for-giant-cell-arteritis-a-systematic-review-and-meta-analysis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/smoking-as-a-risk-factor-for-giant-cell-arteritis-a-systematic-review-and-meta-analysis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology